Literature DB >> 5411448

Fibrin degradation products in sera of women with normal menstruation and menorrhagia.

H K Basu.   

Abstract

Serum concentrations of fibrin degradation products were found to be higher during menstruation than in the intermenstrual phase. Higher concentrations were present in cases of menorrhagia as compared with healthy women and women with various gynaecological disorders but with normal menstrual function. Higher serum concentrations of fibrin degradation products in cases of menorrhagia may indicate increased local fibrinolytic activity in the uterus.

Entities:  

Mesh：

Substances：

Year:  1970        PMID： 5411448      PMCID： PMC1699183          DOI： 10.1136/bmj.1.5688.74

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


  12 in total

1.  Oxygen saturation and spontaneous fibrinolytic activity.

Authors:  R L CLARKE; E E CLIFFTON
Journal:  Am J Med Sci       Date:  1962-10       Impact factor: 2.378

2.  Use of protamine sulfate and toluidine blue for abnormal uterine bleeding.

Authors:  W L RUMBOLZ; C F MOON; J C NOVELLI
Journal:  Am J Obstet Gynecol       Date:  1952-05       Impact factor: 8.661

3.  A double blind study of the effect of tranexamic acid in essential menorrhagia.

Authors:  J Vermylen; M L Verhaegen-Declercq; M Verstraete; F Fierens
Journal:  Thromb Diath Haemorrh       Date:  1968-12-31

4.  Treatment of menorrhagia with epsilon aminocaproic acid. A double blind investigation.

Authors:  L Nilsson; G Rybo
Journal:  Acta Obstet Gynecol Scand       Date:  1965       Impact factor: 3.636

5.  Plasminogen activation and the coagulation process.

Authors:  C R Prentice; G P McNicol; A S Douglas
Journal:  J Clin Pathol       Date:  1969-05       Impact factor: 3.411

6.  Plasminogen activators in the endometrium. II. Clinical aspects. Variation in the concentration of plasminogen activators during the menstrual cycle and its relation to menstrual blood loss.

Authors:  G Rybo
Journal:  Acta Obstet Gynecol Scand       Date:  1966       Impact factor: 3.636

7.  Quantitative estimation of split products of fibrinogen in human serum, relation to diagnosis and treatment.

Authors:  C Merskey; G J Kleiner; A J Johnson
Journal:  Blood       Date:  1966-07       Impact factor: 22.113

8.  Fibrin degradation products in sera of normal subjects.

Authors:  P C Das; A G Allan; D G Woodfield; J D Cash
Journal:  Br Med J       Date:  1967-12-23

9.  EXPERIENCES WITH EPSILON-AMINOCAPROIC ACID (EPSILON-ACA) IN THE TREATMENT OF PROFUSE MENSTRUATION.

Authors:  I M NILSSON; S E BJOERKMAN
Journal:  Acta Med Scand       Date:  1965-04

10.  Fibrinolytic components of human uterine arterial and venous blood.

Authors:  A V Mackay; P C Das; P R Myerscough; J D Cash
Journal:  J Clin Pathol       Date:  1967-05       Impact factor: 3.411
View more
  7 in total

1.  Physiology of abnormal bleeding.

Authors:  E Cope
Journal:  Br Med J       Date:  1971-06-05

2.  The treatment of unexplained menorrhagia.

Authors:  E Cope
Journal:  Ir J Med Sci       Date:  1983-06       Impact factor: 1.568

Review 3.  Clinical applications of fibrinolytic inhibition in gynaecology.

Authors:  J Bonnar; J Guillebaud; J M Kasonde; B L Sheppard
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1980

4.  Danazol in the treatment of menorrhagia.

Authors:  E Cope
Journal:  Drugs       Date:  1980-05       Impact factor: 9.546

5.  Menstrual blood loss and fibrin degradation products.

Authors:  S K Cole; A R Clarkson
Journal:  Br Med J       Date:  1972-01-08

Review 6.  Complications associated with orthognathic surgery.

Authors:  Young-Kyun Kim
Journal:  J Korean Assoc Oral Maxillofac Surg       Date:  2017-02-20

Review 7.  Perioperative hyperfibrinolysis - physiology and pathophysiology.

Authors:  David Silveira Marinho
Journal:  Braz J Anesthesiol       Date:  2020-12-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.